Pain reduction was a secondary endpoint. You can only do statistical analysis on a secondary endpoint if your study meets its primary endpoint. The FDA won't approve a treatment on a secondary endpoint if the primary endpoint is not met - they will just tell you to go off and run another Phase III trial and come back later.
This is exactly what happened in the CHF trial - a great result stuffed by terrible trial design. Heads need to roll.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-174
-
- There are more pages in this discussion • 930 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
98.0¢ |
Change
-0.015(1.51%) |
Mkt cap ! $1.124B |
Open | High | Low | Value | Volume |
$1.00 | $1.01 | 97.5¢ | $601.0K | 608.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 46246 | 97.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
98.0¢ | 50737 | 28 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 26590 | 0.975 |
16 | 206072 | 0.970 |
12 | 230585 | 0.965 |
11 | 631641 | 0.960 |
2 | 14825 | 0.955 |
Price($) | Vol. | No. |
---|---|---|
0.980 | 51927 | 27 |
0.985 | 31684 | 12 |
0.990 | 38395 | 24 |
0.995 | 57668 | 4 |
1.000 | 95828 | 8 |
Last trade - 11.15am 20/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |